APR 11, 2018 09:00 AM PDT

Conversion of Group A Streptococcus Confirmation Testing from Culture to Molecular: Automation, Workflow Improvements and Antimicrobial Stewardship

SPONSORED BY: Diasorin, Inc.
C.E. CREDITS: P.A.C.E. CE | Florida CE
  • System Director, Clinical and Molecular Biology at Geisinger Diagnostic Medicine Institute
      Dr. Donna Wolk is the System Director for Clinical and Molecular Microbiology at Geisinger Health System, an integrated delivery system in Pennsylvania. As a Diplomate of the American Board of Medical Microbiology (ABMM), Dr. Wolk's professional practice extends to the national and international level, supporting initiatives in clinical and molecular microbiology and laboratory leadership. Active in the American Society of Microbiology, among others, she is most well known for her strategic thinking and predications about new technology and its impact to patient care, as well as her work as one of seven founding members of CDC/ASM collaboration for Evidence Based Laboratory Medicine Best Practices. Dr. Wolk was selected as a Clinical Research Scholar at the University of Arizona and in 2012, she received the 1885 Distinguished Scholar Award, which acknowledges outstanding faculty whose research, scholarship, and creative contributions exemplify innovation, service, and success in their respective disciplines. She is the 2016 award laureate, selected by the American Society for Microbiology to receive the BD Award for Clinical Research in Microbiology.


    Streptococcus pyogenes or Group A Streptococcus (GAS) is a pathogenic bacteria that causes both invasive and non-invasive infections resulting in mild to severe life-threatening disease.

    Laboratory guidelines mandate that a more sensitive confirmatory test is performed on negative rapid antigen samples. However, routine culture detection of the organism can take an additional 24-48 hours. As an alternative, rapid molecular testing for Group A Strep can offer a faster and more efficient method for confirmation, contributing to the accelerated treatment of the patient.

    During this presentation you will learn how our laboratory implemented a rapid, automated highthroughput method for molecular confirmation of rapid antigen negatives. The advantages of moving this assay from culture to molecular in terms of workflow and increased sensitivity will be discussed.

    Show Resources
    Loading Comments...